Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05614349 | Canadian Adaptive Platform Trial of Treatments for COVID-19 in Community Settings | PHASE3 | ACTIVE NOT_RECRUITING | 797 | — | — | Jan 16, 2023 | Jun 28, 2025 | May 16, 2025 | 6 | Canada |
| Arm | Type | Description |
|---|---|---|
| Paxlovid | EXPERIMENTAL | Nirmatrelvir/ritonavir (Paxlovid™) BD x 5 days (this arm has been closed of Sept 30th 2024) |
| Control group | NO_INTERVENTION | Usual care (i.e., supportive care and symptom relief) |
| Antioxidant Therapy - Intervention (arm 3) | EXPERIMENTAL | Antioxidant therapy (comprising of selenium, zinc, lycopene, and vitamin C) |
| Name | Type | Description |
|---|---|---|
| Paxlovid | DRUG | This adaptive platform trial will assess therapeutics for SARS-CoV-2 in out-patient settings. The first intervention arm is Paxlovid. |
| Antioxidant | DRUG | Antioxidant therapy (comprising of selenium, zinc, lycopene, and vitamin C) |
Inclusion Criteria: * Age 50 years and older or 18-49 with 1 or more chronic high-risk medical conditions, and/or immunosuppression: chronic respiratory disease (including COPD, cystic fibrosis and asthma requiring at least daily use of preventative and/or reliever medication); chronic heart or vas...